Table 4.
Factors leading to treatment initiation (females with VUS excluded)
| Factors | N = 31 n (%) |
|---|---|
| Neuropathic pain | 6 (19.4) |
| Proteinuria | 1 (3.2) |
| GFR decreased | 1 (3.2) |
| Stroke | 2 (6.5) |
| TIA | 1 (3.2) |
| Cardiac disease | 12 (38.7) |
| GI symptoms | 1 (3.2) |
| Exercise intolerance and hypohidrosis | 2 (6.5) |
| Lyso-Gb3 increased | 1 (3.2) |
| Angiokeratoma | 3 (9.7) |
| Othera | 17 (54.8) |
Multiple answer, the sum of percentages can be greater than 100%
α-Gal-A, alpha galactosidase A; TIA, transient ischemic attack
aMainly: GLA variant detection (n = 3), confirmatory renal biopsy (n = 3) and acroparesthesias (n = 2); other factors selected by physicians included access to the drug, decreased α-Gal A, presence of cornea verticillata, chronic venous insufficiency or microalbuminuria